Is your drug product manufactured outside of the United States? Do you have challenging dosing milestones?
Implementing a Pre-IND packaging strategy will expedite your upstream timeline to ensure you meet your first patient-in milestones while you await your FDA approval and IND number.
In this recording, Sharlett Burgess (Quality Director of Canada) and Jackie Newell (Business Development Executive) discusses the in’s and out’s of the Pre-IND speed-to-study® offering, including the quality and regulatory considerations, and how introducing this process into your overall clinical supply strategy will accelerate your trial and attain your FPI milestones.
Expedite your clinical study with a Pre-IND speed-to-study® Strategy (Audio – MP3)
We provide a complete clinical trial management service and we are committed to supporting clients at every stage of the clinical cycle, delivering best-in-class services efficiently and effectively.
Accelerate your drug to proof of concept with PCI’s speed-to-study® services.